# Clinical Translational Research Core

> **NIH NIH P30** · JOSLIN DIABETES CENTER · 2024 · $284,346

## Abstract

CLINICAL TRANSLATIONAL RESEARCH CORE: Abstract
The Joslin Clinical Translational Research Core (CTRC) provides infrastructure for the conduct of high-quality
clinical and translational research in diabetes and metabolism. This is done by facilitating access to appropriate
patient populations as well as providing specialized facilities and expertise focused on clinical research related
to the pathophysiology, prevention and treatment of diabetes, its complications, and related metabolic disorders.
Since it was established in the last funding cycle, the CTRC has provided consultative services for study design
and regulatory guidance. Physical infrastructure and well-trained nusing and technical staff assist investigators
in safely carrying out gold standard euglycemic, hyperglycemic, and hypoglycemic clamps at physiologic or
pharmacologic insulin concentrations; intravenous and oral glucose and mixed meal tolerance tests; and other
metabolic testing to assess insulin secretion, insulin action, and other physiologic processes for patient-centered
research specific to diabetes and metabolism. In addition expertise and equipment are available for exercise
training and testing capacities, dual-energy X-ray absorptiometry for assessment of bone density and body
composition, electroretinogram and optical coherence tomography angiography for visualization of retinal
function and vasculature, continuous glucose monitor data analayses, cooling vests for brown fat activation,
metabolic assessments, bioimpedance analysis, and anthropometry. CTRC facilities and procedures allow for
the sampling of various biologic fluids, performance of pharmacokinetic and pharmacodynamic studies and
physiologic measurements, and protocols for skin, muscle and adipose tissue sampling. Additionally, the Core
has established a diabetes-specific Biorepository that facilitates discovery of and access to biospecimens and
linked data. In this application, we propose to provide resources for “T1” translational research programs with
specific focus on prediction, prevention, and interdiction of type 1 or type 2 diabetes and related complications;
to facilitate design, implementation, and evaluation of investigator-initiated clinical trials and epidemiologic
studies for “T2-T3” research programs focused on improving/optimizing treatments of diabetes and related
complications; and to expand the CTRC Biorepository. These represent efforts that will build research capacity
for translating new discoveries into improvement in the treatment, prevention and ultimately, the cure of diabetes.

## Key facts

- **NIH application ID:** 10847345
- **Project number:** 5P30DK036836-38
- **Recipient organization:** JOSLIN DIABETES CENTER
- **Principal Investigator:** LORI M LAFFEL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $284,346
- **Award type:** 5
- **Project period:** 1997-02-15 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10847345

## Citation

> US National Institutes of Health, RePORTER application 10847345, Clinical Translational Research Core (5P30DK036836-38). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10847345. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*